http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research
-
Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development
-
Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
-
Revvity to Present at Goldman Sachs Global Healthcare Conference
-
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
-
Revvity Announces Financial Results for the First Quarter of 2023
-
Launching Revvity: A Scientific Solutions Company Powering Innovation from Discovery to Cure
-
PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows
-
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2022
-
PerkinElmer To Hold Earnings Call on Tuesday, February 14, 2023; Updates Fourth Quarter Outlook
-
PerkinElmer Helps Accelerate Gene Therapy Research with Industry-First Ready-to-Use Viral Vector Assays
-
PerkinElmer (PKI) Announces FDA Marketing Authorization for EONIS SCID-SMA Kit
-
PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns
-
PerkinElmer Announces Financial Results for the Third Quarter of 2022
-
PerkinElmer Bolsters Sustainability Commitments and Builds Off Recent Progress in New ESG Report
-
EPIC SCIENCES EXPANDS EXECUTIVE TEAM AND WELCOMES NEW CHIEF FINANCIAL OFFICER IN PREPARATION FOR RAPID GROWTH
-
PerkinElmer (PKI) Updates Third Quarter Outlook
-
PerkinElmer to Hold Earnings Call on Tuesday, November 8, 2022; Updates Third Quarter Outlook
-
PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana
-
PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing
-
PerkinElmer's (PKI) Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection
-
PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection
-
PerkinElmer (PKI) Names New CFO
-
PerkinElmer Announces Finance Leadership Transition
-
New Mountain Capital Announces Intent to Acquire PerkinElmer’s Applied, Food and Enterprise Services Businesses for up to $2.45 Billion
-
PerkinElmer (PKI) Reports Q2 Revenue of $1.23B, EPS of $1.42
-
PerkinElmer Announces Financial Results for the Second Quarter of 2022
-
PerkinElmer (PKI) to Divest Applied, Food and Enterprise Services for $2.45B Cash
-
PerkinElmer Accelerates Transformation into High Growth, High Margin Life Sciences & Diagnostics Company
-
PerkinElmer (PKI) Appoints Michelle McMurry-Heath to its Board
-
PerkinElmer Elects Dr. Michelle McMurry-Heath to its Board of Directors
-
PerkinElmer Introduces Next Generation, Automated Gas Chromatography Platform
-
PerkinElmer Launches BioQule NGS System to Automate Library Preparation
-
PerkinElmer Announces Financial Results for the First Quarter of 2022
-
PerkinElmer Expands In Vivo Instruments Portfolio with Hands-free, High-throughput Vega® Widefield Preclinical Ultrasound Imaging System
-
PerkinElmer Introduces First Ready-to-use HTRF® and AlphaLISA® Assay Kits for CHO HCP Impurities Detection and Quantification
-
PerkinElmer's (PKI) EUROIMMUN Cited by CDC in its Two-Step Testing Algorithm for Dengue Virus
-
U.S. Centers for Disease Control Guidance Includes EUROIMMUN Assay in its Two-Step Testing Algorithm for Dengue Virus
-
PerkinElmer Announces Financial Results for the Fourth Quarter and Full Year of 2021
-
Phase II Clinical Trial Data Establishes Effectiveness of using a Child’s Own Cord Blood to Treat Cerebral Palsy
-
Phase I Clinical Trial Examines Safety of Using Cord Blood Stem Cells for Treating Children with Autism Spectrum Disorder
-
Varian Medical Systems Announces Agreement to Acquire PerkinElmer's Medical Imaging Business; $276 Million Acquisition to Expand Digital Flat Panel Business for Varex Imaging
-
Highlights From CRM's Q2 Conference Call: Continued Demand Shift to Enterprise Cloud Computing

